Kornimate/medical-research-clean huggingface dataset:
caesarean scar revision with the ultrapulse

Conditions: Scar Revision

Summary: ten (10) adult female subjects that had a caesarean surgery performed.study will be conducted in 1 site. each subject will receive three treatments on one area that was randomly chosen. the other area will be left untreated and will serve as a control. the objective is to evaluate the clinical impact of ultrapulse fractional carbon dioxide laser treatment on the appearance of a caesarean scar (cs) as compared to a similar untreated scar side.


Eligibility criteria:
inclusion criteria: 1. females in good general health older than 22 years of age and younger than 55 years of age. 2. presenting with a caesarean scar mature and stable caesarean scar (at least 1 year post procedure). 3. at least six months following termination of breast feeding. 4. willing to give and sign an informed consent form and a photographic release form. 5. willing to comply with study dosing and complete the entire course of the study . 6. performed negative pregnancy test. exclusion criteria: 1. active bacterial, fungal, or viral infection in the treatment area. 2. active cold sores, or herpes in the treatment area. 3. recent excessive exposure to sunlight or artificial uv light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study . 4. history of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis). 5. treatment with a systemic retinoid within the past year (e.g., accutane®, roche dermatologics). 6. history or presenting with a keloid scar. 7. any current or recent treatment for cancer. 8. any uncontrolled systemic disease. a potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study. 9. significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study. 10. previous laser treatments on the same scar at least 0.5 year prior to this evaluation. 11. subject planning any other cosmetic procedure to the study area during the study period, other than the treatments that will be performed by the investigator . 12. any other condition that may exclude patient for treatment per physician discretion. 13. female subject who is pregnant, nursing an infant .
contrast ice for myocardial scar in vt ablations

Conditions: Ventricular Tachycardia; Ischemic Cardiomyopathy

Summary: there is a high correlation between scar areas identified by contrast-enhanced ice and scar areas identified by conventional electroanatomic mapping. therefore, the investigators will assess the utility of contrast-enhanced ice to identify and localize myocardial scar real-time during vt ablation procedures.

ventricular tachycardia (vt) is a life-threatening arrhythmia which occurs frequently in the setting of structural heart disease, most often as result of myocardial fibrosis or scar. catheter ablation is often performed to treat recurrent vt, but is predicated on precise localization of myocardial scar, as scar is often the source of vt. currently during vt ablation procedures the identification of scar is based on electroanatomic mapping where bipolar voltage criteria have been established (i.e., bipolar electrogram voltage \< 1.5 mv is considered scar). however this definition is purely based on electrical signal information and so has significant limitations: 1) there has not been definitive establishment of the sensitivity and specificity of this threshold for defining scar in comparison with tissue; 2) a detailed 3-d map created by time-consuming movement of the mapping catheter must be obtained in order to assess the existence and location of the scar; 3) only scar on the surface in contact with the mapping catheter (most often endocardial) may be definitively identified, whereas there may be intramyocardial or epicardial scar that would not be identified unless the mapping catheter makes direct contact with those areas which may involve additional risky access (epicardial) or even impossible (intramyocardial). for these reasons it would be very helpful to have another method to identify and localize myocardial scar during a vt ablation procedure. cardiac mri has been validated for identifying and localizing scar, but would not be recommended for many patients due to presence of icd (implantable cardioverter-defibrillator) devices in these patients. contrast-enhanced echocardiography has been validated to identify myocardial scar (montant 2010), and intracardiac echocardiography (ice) is standardly used in vt ablation procedures. therefore, the investigators will assess the utility of contrast enhanced ice by identifying and localizing myocardial scar real-time during vt ablation procedures.

Eligibility criteria:
inclusion criteria: * subject is 18 years of age or older * subject is undergoing catheter ablation of likely reentrant vt * planned use of intracardiac echocardiography (ice) * subject is willing to sign and date the study informed consent form exclusion criteria: * contraindication to perflutren (optison) echo contrast * known right-to-left, bidirectional, or transient right-to-left cardiac shunts * known hypersensitivity to perflutren, blood, blood products or albumin * subject has medical condition that would limit study participation (as per md discretion) * subject is pregnant * inability to give informed consent
long term extension study for the maintenance treatment of anemia associated with chronic kidney disease (ckd) in hemodialysis subjects on epoetin alfa / beta treatment versus bay85-3934

Conditions: Anemia; Renal Insufficiency, Chronic

Summary: evaluate efficacy and safety up to 36 months of titrated dose treatment with bay85-3934 versus epoetin alfa/beta. titration will be based on the subject's hemoglobin (hb) response and tolerability of the prior dose. planned doses include 15, 25, 50, 75, 100,and 150 mg once daily.


Eligibility criteria:
inclusion criteria: * eligible male or female subjects were previously enrolled in study 16208, have a diagnosis of anemia associated with ckd, and are on hemodialysis. * men who agree to use adequate contraception when sexually active or women without childbearing potential * participation and completion of treatment in study 16208; subjects must have received 16 weeks of study medication and completed the end of treatment visit (day 113) in the parent study * mean hb concentration of 9.5 to 11.5 g/dl, inclusive, during the evaluation period (i.e., the last 4 weeks of the parent study) when the subject completed 16 weeks of treatment with bay85-3934, epoetin alfa, or epoetin beta in study 16208 exclusion criteria: * a scheduled kidney transplant or any other organ transplant within the next 6 months (being on a waiting list does not exclude the subject) * updates to medical and surgical history which meet the exclusion criteria in the parent study * subjects treated with immunosuppressive therapy and the breast cancer resistant protein (bcrp) substrates, irinotecan, topotecan, methotrexate, imatinib, and lapatinib * sustained, poorly controlled arterial hypertension or hypotension at baseline, defined as mean bp ≥ 180/110 mmhg or systolic bp \< 95 mmhg, respectively * severe rhythm or conduction disorder (e.g., hr \ 110 bpm, atrial fibrillation or flutter, prolonged qt \> 500 msec, second or third degree atrioventricular \[av\] block) * new york heart association class iii or iv congestive heart failure * severe hepatic insufficiency (defined as alanine aminotransferase \[alt\], aspartate aminotransferase \[ast\], or gamma-glutamyl transferase \> 3 x the upper limit of norma \[uln\], total bilirubin \> 2 mg/dl, or child-pugh b or c) or active hepatitis in the investigator's opinion * an ongoing sae from study 16208 that is assessed as related to study drug * alcohol or drug abuse

Keywords: anemia of ckd on dialysis
behavioral change communication (bcc) to promote physical activity among females with type 2 diabetes mellitus attending diabetic clinic

Conditions: Type 2 Diabetes Mellitus

Summary: type 2dm is present in the populations of almost all the countries in the world and is a significant disease burden in most countries .evidences suggest that population in india develop type 2 dm at an increasing rate as they reject their traditional life styles. awareness and knowledge regarding diabetes and role of physical inactivity in producing complications is still grossly inadequate( mohan. d, raj.d awareness and knowledge of diabetes in chennai.the chennai urban rural epidemiology study(cures-9)j assoc. physicians india 2005 april;53:283-7).exercise is a low cost , non pharmacological intervention that has been shown to be effective in metabolic control. exercise is still vastly under-utilized in the management of type 2 dm. most proximal behavioral cause of insulin resistance is physical inactivity.(michael j. lamonte, steven n. blair et al.( physical activity and diabetes prevention j appl physiol. 99: 1205-1213,2005) this study was designed to promote physical activity among type 2 dm female subjects aged 35-65 yrs attending diabetic clinic of a tertiary care hospital in kerala.

the bcc model consisted of 1.an audio visual module imparting knowledge about dm, its complications, advantages of pa in diabetes control, how to include more pa in routine life style 2. pamphlets.all these were standardised. physical activity was measured using international physical activity questionnaire validated(responsiveness\& reliability) for our cultural activity.ipaq covers four domains of physical activity: work-related,transportation, housework/gardening and leisure-time activity. pa data from the questionnaire were transformed into energy expenditure estimates as met using published values. to calculate the weekly physical activity (met-h /week), the number of hours dedicated to each activity class was multiplied by the specific met score for that activity. follow up once in a month (4 times) measure incremental physical activity and reinforcement in each visit. students t test was used to compare the experimental and control groups with respect to the incremental physical activity measured in calorie expenditure. it was found that the incremental physical activity(final-basal) measured in mets is significantly higher in intervention group.

Eligibility criteria:
inclusion criteria: * females 30to 65yrs. with type-2 diabetes mellitus. * attending diabetic clinic at a tertiary level hospital(medical college thiruvananthapuram) * on oral hypoglycemics exclusion criteria: * only one patient from one family * h/o myocardial infarction * nephropathy * autonomic neuropathy * severe limiting osteo arthritis * pregnancy * mental incompetence

Keywords: physical activity diabetes mellitus behavioral change communication household physical activity
sofosbuvir plus daclatasvir with or without ribavirin and chronic hcv genotype (gt) 4

Conditions: Chronic Hepatitis C Virus Infection

Summary: this study aims to evaluate the efficacy and safety of dcv plus sofosbuvir (sof) with or without ribavirin (rbv) for treatment of egyptian participants infected with hcv gt4.

egyptian participants infected with hcv gt4 were classified into two groups: group 1 (easy to treat) was treated with a dual therapy of sof/dcv daily for 12 weeks and group 2 (difficult to treat) was treated with a triple therapy of sof/dcv/rbv daily for 12 weeks. sof dose was 400 mg/day given orally dcv was given in a dose of 60 mg/day, orally. rbv was given as oral tablets in the morning and in the evening based on patient's weight and tolerability (starting dose 600 mg/day to reach 1200 mg/day.

Eligibility criteria:
inclusion criteria: * non-cirrhotic treatment-naïve participants * fib-4 \< 3.25 * albumin \> 3.5 * total bilirubin \< 1.2 mg/dl * international normalized ratio (inr) \< 1.2 * platelet count \> 150,000 mm3. * experienced participants who had previously failed treatment with peg-ifn-α-/rbv, sof/peg-ifn-α +rbv, or sof/smv * naïve cirrhotic participants were confirmed by ultrasonographic features of cirrhosis exclusion criteria: * liver disease of non-hcv etiology * hepatitis b or human immune-deficiency virus (hiv) infection * poorly controlled diabetic (hba1c \> 9) participants * hepatocellular carcinoma * a history of extra-hepatic malignancy within 5 years prior to the study * pregnant or breast feeding * renal disease; serum creatinine \> 2.5 mg/dl or egfr \< 30 ml/min * evidence of hepatic decompensation; inr \> 1.7, serum albumin \ 3 mg/dl * blood picture abnormalities such as anemia (hemoglobin concentration of 10 g/dl or less) and thrombocytopenia (platelet count \< 50,000 cells/mm3) * major severe illnesses such as congestive heart failure and respiratory failure.

Keywords: sofosbuvir daclatasvir ribavirin hcv gt 4
fish oil and asthma in house dust mite allergy

Conditions: Allergic Asthma; Bronchial Inflammation; House Dust Mite Allergy

Summary: native populations consuming high amounts of fish suffer less from allergic diseases. the purpose of this study is to determine whether polyunsaturated fatty acids (fish oil) might have a disease modifying influence on asthmatics sensitized to house dust mite.

most asthmatics suffer from mild disease and non pharmacologic intervention would be beneficial for the majority of these subjects. we investigated the anti-inflammatory potential of polyunsaturated fatty acids (pufa) in allergic asthma. in our parallel, double-blinded study, 23 patients allergic to house dust mite were randomly assigned to dietary supplementation with a pufa enriched fat blend or placebo for five weeks. the verum contained eicosapentaenoic acid (epa) 450 mg/day, docosahexaenoic acid 180 mg/day, stearidonic acid 60mg/day, and gamma-linolenic acid 60 mg/day; the placebo consisted of mainly unsaturated and monosaturated fatty acids. after three weeks, the patients were challenged with low doses of inhalative house dust mite allergen for two weeks. following parameters were determined during low-dose allergen exposure in both groups: exhaled no (eno) as a marker of bronchial inflammation, clinical symptoms, fev1, beta-agonist usage, and bronchial hyperreactivity, sputum eosinophils and sulfoleucotrienes. compliance with the study protocol was controlled by the determination of pufas in plasma and erythrocytes.

Eligibility criteria:
inclusion criteria: * allergic sensitization to house dust mite as proven by skin test and specific ige * normal lung function, episodic asthma exclusion criteria: * history of hypersensitization towards fish oil, chronic illness, pregnancy

Keywords: polyunsatturated fatty acids nutrition low-dose allergen challenge exhaled nitric oxide
investigation of low-intensity focused ultrasound for human pain management

Conditions: Chronic Pain

Summary: this project examines the effects of noninvasive brain stimulation on pain. the investigators believe this study will help to better understand possible treatments for chronic pain patients. participants undergo structural imaging, a functional magnetic resonance image (fmri) and computed tomography (ct). these images are used to align the low-intensity focused ultrasound (lifu) device which uses sound waves to temporarily change brain activity. pain testing is done using a small device that will increase/decrease the temperature of the skin. brain signals are collected using electroencephalography (eeg). heart rate, blood pressure, and skin moisture will be monitored as well.


Eligibility criteria:
inclusion criteria: * understand and speak english exclusion criteria: * mri/ct/eeg contraindications. 1. claustrophobia 2. contraindications to mri: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants. 3. contraindications to ct: pregnancy 4. active medical disorder or treatment with potential cns effects 5. history of neurologic disorder 6. history of head injury resulting in loss of consciousness for \>10 minutes. 7. history of alcohol or drug dependence 8. failure to provide social security number or tax id number. this is required for tax purposes or payment cannot be processed.

Keywords: low-intensity focused ultrasound
evaluation of cell membrane expression of annexin a2 on monocytes by flow cytometry in primary antiphospholipid syndrome

Conditions: Antiphospholipid Syndrome

Summary: annexin a2 (anxa2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in antiphospholipid syndrome (aps). anxa2 can exist as a monomer or a heterotetrameric complex with s100a10 protein. the aim of this study was to evaluate the cell membrane expression of anxa2 on circulating monocytes in aps by flow cytometry. several pathogenic mechanisms are involved in aps such as activation of endothelial cells, platelets and monocytes, inhibition of the natural anticoagulant protein c/protein s pathway, activation of the complement system and also impairment of fibrinolysis. annexin a2 which hits binding partner s100a10, anxa2 forms a cell surface complex that regulates generation of plasmin. anxa2 is involved in the pathogenesis of aps-associated through several possible mechanisms. human peripheral blood monocytes represent the major circulating anxa2-expressing cell and anxa2-mediated assembly of plasminogen and tissue activator of plasminogen (tpa) on monocyte/macrophages contributes to plasmin generation. thus the investigators could suppose that decrease of cell membrane expression of anxa2 on circulating monocytes represent a new pathogenic mechanism in aps.


Eligibility criteria:
inclusion criteria: * aps patients who fulfilled the revised criteria for aps exclusion criteria: * patients less than 18 years old * solid and hematological malignancies * other autoimmune diseases * cirrhosis

Keywords: annexin a2 antiphospholipid syndrome monocytes
incidence of psoriatic arthritis among psoriasis patients newly initiated with secukinumab in a us claims database and a uk registry

Conditions: Psoriatic Arthritis; Psoriasis

Summary: this was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (psa) among psoriasis (pso) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). the analysis was performed in two databases, ibm® marketscan® database: commercial claims and encounters (ccae) and medicare supplemental beneficiaries (mdcr) from 01 january 2010 to 30 june 2021 and badbir from 01 january 2016 to 01 september 2021.


Eligibility criteria:
marketscan® secukinumab cohort: inclusion criteria: * included patients with at least 1 secukinumab claim between 01 january 2015 and 30 june 2020 (index date is the first secukinumab claim) * included patients age ≥18 years as of the year of index date * included patients with at least 1 non-ruleout psoriasis diagnosis during 2 years of pre-index period * included patients with continuous medical/pharmacy coverage in the 2-year pre-index period * included patients with continuous medical/pharmacy coverage in the 1-year post-index period exclusion criteria: * excluded patients with any psoriatic arthritis diagnosis during 2 years to 5 years pre-index period, as well as on the index date * excluded patients with any biologics/apremilast including secukinumab claim during the 2-year pre-index (excluding index date) * excluded patients received other non-secukinumab biologics/apremilast during 6 months post index date period (including index date) (this criterion is only applicable for the secukinumab cohort) badbir cohort: inclusion criteria: * included non-switched patients with secukinumab treatment on or after the enrollment between 01 january 2017 to 01 september 2020 * non-switched patients are those who did not use other biologics/apremilast treatments on the enrollment date * index date will be the date of the first secukinumab treatment date * included patients with age ≥ 18 on the index date * included patients with psoriasis diagnosis in the pre-index period and index date * included patients with ≥ 1 year follow-up period * follow-up period is the gap between patient's last visit date and index date exclusion criteria: * excluded patients with psoriatic arthritis (psa) prior to and on index date * excluded patients with any biologics/apremilast including secukinumab in the baseline period
is eovist suitable for arterial-phase mr imaging of liver

Conditions: Liver Disease

Summary: to examine the quality of liver images produced when the contrast agent eovist is used during mri.

researchers will review data from the eovist mri and compare the scan with previous mri exams the patient had with the same or other contrast agents. to determine the efficacy of eovist contrast agent in producing mri images of the liver. we will monitor patients for any unusual symptoms (adverse events) when the contrast is given. patients are asked to hold their breath during an mri scan. eovist may interfere with the "breath hold" which could result in more breathing artifacts (based on a qualitative scale) on arterial images when the patients are given eovist vs. other contrast agents.

Eligibility criteria:
inclusion criteria: 1. you have had a scheduled mri(magnetic resonance imaging) scan using the contrast agent eovist. 2. male and females 21 years of age or older. exclusion criteria: 1. does not have a contraindication for mri (e.g. cardiac pacemaker, ferromagnetic or metallic implants). 2. pregnancy